The Global Tribune

Gastric Neuroendocrine Tumors Competitive Landscape Report 2020: Emerging Therapies and Key Pharma players involved

 Breaking News
  • No posts were found

Gastric Neuroendocrine Tumors Competitive Landscape Report 2020: Emerging Therapies and Key Pharma players involved

February 25
22:22 2021
Gastric Neuroendocrine Tumors Competitive Landscape Report 2020: Emerging Therapies and Key Pharma players involved

DelveInsight Business Research LLP
“Gastric Neuroendocrine Tumors Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Gastric Neuroendocrine Tumors market. A detailed picture of the Gastric Neuroendocrine Tumors pipeline landscape is provided, which includes the disease overview and Gastric Neuroendocrine Tumors treatment guidelines.

Gastric Neuroendocrine Tumors Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Gastric Neuroendocrine Tumors market. A detailed picture of the Gastric Neuroendocrine Tumors pipeline landscape is provided, which includes the disease overview and Gastric Neuroendocrine Tumors treatment guidelines.

Gastric neuroendocrine tumors (NETs), which previously were classified as Gastric Carcinoids, are neoplasms derived from the enterochromaffin-like cells (ECL cells) of the gastric mucosa. They are rare lesions with indolent behavior and neuroendocrine differentiation. Although uncommon, the diagnosis has improved, due to the widespread use of upper digestive endoscopy and the technical refinement of endoscopists.

Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/gastric-neuroendocrine-tumors-pipeline-insight

“The prevalence per 10,000 population obtained from cancer registries was 0.32 for Europe; and 0.17 for the US.”

Key pharma players involved:

1. Progenics Pharmaceuticals

2. ITM Isotopen Technologien Muenchen

3. Amgen

4. Ignyta

Emerging Therapies Involved:

1. Iobenguane I-131

2. 177Lu-edotreotide PRRT

3. AMG 479

4. Entrectinib

Click here and download a free sample copy of the report.

Table of contents:

1. Report Introduction

2. Gastric Neuroendocrine Tumors

3. Gastric Neuroendocrine Tumors Current Treatment Patterns

4. Gastric Neuroendocrine Tumors- DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Gastric Neuroendocrine Tumors Late Stage Products (Phase-III)

7. Gastric Neuroendocrine Tumors Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Gastric Neuroendocrine Tumors Discontinued Products

13. Gastric Neuroendocrine Tumors Product Profiles

14. Gastric Neuroendocrine Tumors Key Companies

15. Gastric Neuroendocrine Tumors Key Products

16. Dormant and Discontinued Products

17. Gastric Neuroendocrine Tumors Unmet Needs

18. Gastric Neuroendocrine Tumors Future Perspectives

19. Gastric Neuroendocrine Tumors Analyst Review  

20. Appendix

21. Report Methodology

Download report: https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/